The systems are designed to deliver paresthesia-free pain relief in minutes. They are designed with Boston Scientific’s Fast-Acting Sub-perception Therapy (FAST) and have four MRI conditional, Bluetooth-enabled, rechargeable and non-rechargeable implantable pulse generators.
“We have found that the specific targeting and stimulation parameters of FAST uniquely engage the surround inhibition mechanism to produce rapid and robust pain relief,” Warren Grill, Duke University biomedical engineering professor, said in a news release. “What sets FAST apart from other forms of SCS is that we understand the underlying mechanism, which helps define clinical practices to optimize patient outcomes.”
WaveWriter Alpha systems are supported by Cognita Solutions to help address common challenges in pain management while raising awareness about drug-free pain management options.
“It is with great enthusiasm that we embark on the next era of personalization with the WaveWriter Alpha SCS systems,” senior VP and president of neuromodulation at Boston Scientific Maulik Nanavaty said. “Combined with our family of innovative and proven solutions for the treatment of chronic pain, including the Vertiflex procedure and radiofrequency ablation, we are helping physicians provide treatments that span the continuum of care so patients can find access to the medical support they need to live better lives.”
WaveWriter Alpha was FDA approved in December 2020 and is indicated for the management of chronic intractable pain of the trunk or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, complex regional pain syndrome types I and II, intractable low back pain and leg pain.